Microcap Ledger Metagenomi Therapeutics, Inc. $MGX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Emeryville, CA
- Fiscal year end
- December 31
- Shares outstanding
- 37,777,105 [10-Q 2026-08-10]
What the company doesAI summary of filing
Metagenomi Therapeutics is a pre-clinical stage genome editing company developing genetic medicines to treat genetic diseases. The company uses proprietary metagenomics-derived gene editing systems, including novel nucleases, base editors, and integration systems, to create therapeutic candidates. Its lead program, MGX-001, targets hemophilia A through site-specific genome integration in the liver and is advancing toward clinical development in 2027; the company is also developing additional programs for secreted protein deficiencies and has a collaboration with Ionis Pharmaceuticals for cardiometabolic disease targets. The company is not yet revenue-generating and funds operations through research collaborations and partnership payments. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$50.54M | −$40.69M | $39.03M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $25.21M | −$87.87M | −$88.89M | $41.72M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $52.30M | −$78.06M | −$109.07M | $27.39M | [10-K 2026-03-05] |
- Quarterly cash burn
- −$20.34M
- Cash runway Estimate
- ~5.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 37,423,917 | [10-Q 2024-11-13] |
| 2025-03-07 | 37,383,472 | [10-K 2025-03-17] |
| 2025-05-07 | 37,381,495 | [10-Q 2025-05-13] |
| 2025-08-05 | 37,533,136 | [10-Q 2025-08-12] |
| 2025-11-05 | 0 | [10-Q 2025-11-12] |
| 2026-03-02 | 37,620,530 | [10-K 2026-03-05] |
| 2026-05-05 | 37,646,858 | [10-Q 2026-05-11] |
| 2026-08-06 | 37,777,105 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2025-03-17; declared effective 2025-03-25 [S-3 2025-03-17]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-09 | Reid Laurence | buy | 19,883 | $1.17 | [4 2026-09-11] |
| 2026-09-09 | Reid Laurence | buy | 117 | $1.18 | [4 2026-09-11] |
| 2026-09-08 | Wein Matthew | sell | 358 | $1.16 | [4 2026-09-10] |
| 2026-09-08 | Irish Jian | sell | 2,140 | $1.16 | [4 2026-09-10] |
| 2026-09-08 | Wapnick Pamela | sell | 1,911 | $1.16 | [4 2026-09-10] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-22 | 8-K | Regulation FD disclosure |
| 2026-09-10 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-06-10 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-11 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-04-27 | DEF 14A | Proxy statement |
| 2026-03-05 | 10-K | Annual report |
| 2026-03-05 | 8-K | Results of operations |
| 2026-01-12 | 8-K | Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2025-11-12 | 10-Q | Quarterly report |
Alerts for $MGX
Email me when Metagenomi Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.